Riik: Kanada
keel: inglise
Allikas: Health Canada
GALANTAMINE (GALANTAMINE HYDROBROMIDE)
MARCAN PHARMACEUTICALS INC
N06DA04
GALANTAMINE
24MG
CAPSULE (EXTENDED RELEASE)
GALANTAMINE (GALANTAMINE HYDROBROMIDE) 24MG
ORAL
30
Prescription
PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS
Active ingredient group (AIG) number: 0144660005; AHFS:
CANCELLED POST MARKET
2021-05-10
1 PRODUCT MONOGRAPH PR MAR-GALANTAMINE ER galantamine hydrobromide extended release capsules 8 mg, 16 mg, 24 mg galantamine base Cholinesterase Inhibitor Marcan Pharmaceuticals Inc. Date of Revision: 77 Auriga Drive, Unit# 4 January 15, 2018 Ottawa, ON, CANADA K2E 7Z7 Control No.: 212078 2 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ............................................................................... 3 SUMMARY PRODUCT INFORMATION ................................................................................................. 3 INDICATIONS AND CLINICAL USE ...................................................................................................... 3 CONTRAINDICATIONS ............................................................................................................................ 3 WARNINGS AND PRECAUTIONS .......................................................................................................... 3 ADVERSE REACTIONS ............................................................................................................................ 7 DRUG INTERACTIONS ........................................................................................................................... 12 DOSAGE AND ADMINISTRATION ...................................................................................................... 14 OVERDOSAGE ......................................................................................................................................... 15 ACTION AND CLINICAL PHARMACOLOGY ..................................................................................... 16 STORAGE AND STABILITY .................................................................................................................. 20 DOSAGE FORMS, COMPOSITION AND PACKAGING ...................................................................... 20 PART II: SCIENTIFIC INFORMATION .............................................................................................. Lugege kogu dokumenti